课题基金 / 基金详情

The impact of non-dysentery Shigella-associated diarrhea in children

The impact of non-dysentery Shigella-associated diarrhea in children
非痢疾志贺氏菌相关性腹泻对儿童的影响
批准号:
10368152
负责人:
Subhra Chakraborty
金额:
$66.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-09 至 2026-02-28

项目摘要

项目成果

Subhra Chakraborty的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT Shigella is a primary cause of moderate-to-severe diarrhea in children living in impoverished areas of the world. Shigella is known for causing dysentery (blood in stool). However, majority of the children infected with Shigella present with watery diarrhea. The current World Health Organization (WHO) guidelines for treatment of shigellosis (in the absence of a rapid, sensitive, simple and inexpensive diagnostic test) recommends treatment with antibiotics when presence of visible blood in stool. Thus, the non-dysentery Shigella associated diarrhea (NDSD) cases would not be treated with antibiotics. Absence of dysentery may not indicate a low risk of death and does not exclude Shigella as a cause of diarrhea. In particularly vulnerable younger children or with malnutrition, identification and treatment of Shigella infection might be life-saving. It may be hypothesized that NDSD cases, if identified quickly, should be treated with antibiotics to improve survival and long-term developmental potential in children. Identification of such cases will require a rapid test to document these infections so that treatment can be initiated promptly, and evidence based. To address these questions, we propose to conduct a prospective longitudinal case control study to understand the pathophysiology of NDSD and the impact of NDSD in children compared to dysentery shigellosis. The children seeking care in the hospital in Bangladesh with diarrhea (both dysentery and NDSD), that is positive for Shigella and a third group with Shigella negative watery diarrhea will be enrolled and prospectively followed. Our study has the following specific aims: AIM 1. Determine morbidity and risk of hospitalization associated with NDSD cases and its impact on nutritional status and cognitive development of the children. AIM 2. Understand the impact of NDSD on gut barrier function, systemic and gut inflammation in children. AIM 3. Evaluate if the simple and rapid test S-RLDT could be applicable for case detection and treatment of shigellosis in the clinical settings of the rural hospitals of the endemic countries. Collectively, our proposed research would broadly impact the field by understanding the pathophysiology of NDSD and the impact of NDSD in child health. This study will help to understand if there is a need to change the current guidelines of shigellosis treatment for better survival and development of the children. This study will also validate a rapid test capable of identifying the patients who will benefit from antibiotics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The impact of non-dysentery Shigella-associated diarrhea in children
  • 批准号:
    10209109
  • 项目类别:
  • 资助金额:
    $40.68万
  • 财政年份:
    2021
  • 负责人:
    Subhra Chakraborty
  • 依托单位:
The impact of non-dysentery Shigella-associated diarrhea in children
  • 批准号:
    10588251
  • 项目类别:
  • 资助金额:
    $66.59万
  • 财政年份:
    2021
  • 负责人:
    Subhra Chakraborty
  • 依托单位:
The impact of non-dysentery Shigella-associated diarrhea in children
  • 批准号:
    10247203
  • 项目类别:
  • 资助金额:
    $52.4万
  • 财政年份:
    2020
  • 负责人:
    Subhra Chakraborty
  • 依托单位:
A novel diagnostic tool to aid vaccine evaluation and surveillance of enterotoxigenic E. coli and Shigella
  • 批准号:
    9751198
  • 项目类别:
  • 资助金额:
    $16.38万
  • 财政年份:
    2018
  • 负责人:
    Subhra Chakraborty
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: